Arris deal

Kabi Pharmacia AB (Sweden) will use ARRS's artificial intelligence technology for an undisclosed Kabi drug discovery program. The technology analyzes data developed from both compound library screening and structure-based drug analysis to generate a predictive model of activity of targeted compounds and receptors. ARRS (South San Francisco) believes that the approach will enable it to use a virtual assay process to design and optimize compounds before they need to be synthesized and tested in the lab. ...